Literature DB >> 32690882

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.

Kira Allmeroth1, Moritz Horn2, Virginia Kroef1, Stephan Miethe1, Roman-Ulrich Müller3,4,5, Martin S Denzel6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32690882      PMCID： PMC7932915          DOI： 10.1038/s41375-020-0989-4

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo.

Authors:  Vasudha Tandon; Ruturajsinh M Vala; Albert Chen; Robert L Sah; Hitendra M Patel; Michael C Pirrung; Sourav Banerjee
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

2.  Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma.

Authors:  Ivyna Pau Ni Bong; Ching Ching Ng; Norodiyah Othman; Ezalia Esa
Journal:  Genes Genomics       Date:  2022-06-11       Impact factor: 2.164

Review 3.  The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.

Authors:  Mark Sellin; Stephanie Berg; Patrick Hagen; Jiwang Zhang
Journal:  Transl Oncol       Date:  2022-06-01       Impact factor: 4.803

4.  Mutagenesis screen uncovers lifespan extension through integrated stress response inhibition without reduced mRNA translation.

Authors:  Maxime J Derisbourg; Laura E Wester; Ruth Baddi; Martin S Denzel
Journal:  Nat Commun       Date:  2021-03-15       Impact factor: 14.919

5.  Moving forward with forward genetics: A summary of the INFRAFRONTIER Forward Genetics Panel Discussion.

Authors:  Asrar Ali Khan; Michael Raess; Martin Hrabe de Angelis
Journal:  F1000Res       Date:  2021-06-08

6.  A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.

Authors:  Katarina Chroma; Zdenek Skrott; Jan Gursky; Jaroslav Bacovsky; Pavel Moudry; Tereza Buchtova; Martin Mistrik; Jiri Bartek
Journal:  Cell Death Dis       Date:  2022-03-04       Impact factor: 8.469

7.  GFPT2/GFAT2 and AMDHD2 act in tandem to control the hexosamine pathway.

Authors:  Virginia Kroef; Sabine Ruegenberg; Moritz Horn; Kira Allmeroth; Lena Ebert; Seyma Bozkus; Stephan Miethe; Ulrich Elling; Bernhard Schermer; Ulrich Baumann; Martin Sebastian Denzel
Journal:  Elife       Date:  2022-03-01       Impact factor: 8.713

8.  A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.

Authors:  Sondra L Downey-Kopyscinski; Sriraja Srinivasa; Alexei F Kisselev
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

9.  Synthesis and Discovery of Ligustrazine-Heterocycle Derivatives as Antitumor Agents.

Authors:  Shitang Ma; Ning Zhang; Jiafu Hou; Shijuan Liu; Jiawen Wang; Baowei Lu; Fucheng Zhu; Peipei Wei; Ge Hong; Tianjun Liu
Journal:  Front Chem       Date:  2022-07-25       Impact factor: 5.545

10.  Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Authors:  Kyung Bo Kim
Journal:  Cancer Drug Resist       Date:  2021-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.